Sanofi and EQT Invest in SpliceBio to Advance Gene Therapy

Cuatrecasas has advised Sanofi Ventures and EQT Life Sciences on a €119 million ($135 million) Series B funding round closed by SpliceBio, a pioneering biotechnology company developing gene therapies using its innovative Protein Splicing technology.

The transaction—which also included the participation of Roche Venture Fund and previous investors such as New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners—represents the largest investment round to date in a healthcare startup in Spain.